

Please type a plus sign (+) inside this box → ☐

(Modified) PTO/SB/21 (8-98)
Approved for through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/936,979	
	Filing Date	September 18, 2001	
	First Named Inventor	William Melvin	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission		Attorney Docket Number	1012-010300US

RECEIVED

MAR 2 10 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINAL FILED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	receipt acknowledgment postcard; USPTO form 1449; cited references
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Irene Pleasure, Reg. No. 45,506, Quine Intellectual Property Law Group P.C.
Signature	<i>Irene J. Pleasure</i>
Date	March 5, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: March 5, 2002			
Typed or printed name	Amelia Groth		
Signature	<i>Amelia Groth</i>	Date	March 5, 2002



COPY OF PAPERS
ORIGINALLY FILED

IDS/#6
4.202

RECEIVED
MAR 20 2002
TECH CENTER 1600,2900

I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231,
On March 5, 2002

Quine Intellectual Property Law Group, P.C.

By

Amelia Groth

Attorney Docket No. 1012-010300US
Client Ref. No. SJK/FP5956610

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

William Melvin, *et al.*

Application No.: 09/936,979

Filed: September 18, 2001

For: ANTIBODIES SPECIFIC FOR
CYP1B1

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.



RECEIVED

MAR 20 2002

TECH CENTER 1600/2900

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,

Irene Pleasure
Reg. No. 45,506

COPY OF PAPERS
ORIGINALLY FILED

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871
Fax: (510) 337-7877

ITP:ag



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/936,979
	Filing Date	September 18, 2001
	First Named Inventor	William Melvin
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	1012-010300US
Date Submitted	March 5, 2002	

RECEIVED
MAR 20 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
COPY OF PAPERS ORIGINALLY FILED						

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	AA	WO	97/12246A		University of Aberdeen	04-03/97		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	AB	Bailey et al. (1998) "Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer" <i>Cancer Research</i> 58(22):5038-41.	
	AC	Bhattacharyya et al. (1995) "Identification of a Rat Adrenal Cytochrome P450 Active in Polycyclic Hydrocarbon Metabolism as Rat CYP1B1" <i>J. Biol. Chem.</i> , 270:11595-602.	
	AD	Crespi et al. (1997) "Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens" <i>Mutagenesis</i> , 12(2):83-9.	
	AE	Duncan et al. (1992) "A simple enzyme linked immunosorbent assay (ELISA) for the neuron-specific γ isozyme of human enolase (NSE) using monoclonal antibodies raised against synthetic peptides corresponding to isozyme sequence differences." <i>J. Immunol. Meth.</i> 151:227-36.	
	AF	Elston & Ellis (1991) "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up." <i>Histopathology</i> , 19:403-410.	
	AG	Hakkola et al. (1997) "Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells." <i>Carcinogenesis</i> 18:391-97.	
	AH	Hayes et al. (1996) "17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1" <i>PNAS, USA</i> 93(18):9776-81.	
	AI	King et al. (1997) "A highly sensitive detection method for immunohistochemistry using biotinylated tyramine." <i>J. Pathol.</i> 183:237-41.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS
ORIGINALY FILED

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/936,979
Filing Date	September 18, 2001
First Named Inventor	William Melvin
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	1012-010300US
Date Submitted	March 5, 2002

RECEIVED

MAR 20 2002

TECH CENTER 1600/2900

AJ	Liehr and Ricci (1996) "4-hydroxylation of estrogens as markers of human mammary tumors" <i>PNAS, USA</i> 93(8):3294-6.
AK	McKay, J. et al. (1995) "Expression of cytochrome P450 CYP1B1 in breast cancer" <i>FEBS Letters</i> , 374:270-2.
AL	Murray et al. (1997) "Tumor-specific expression of cytochrome P450 CYP1B1". <i>Cancer Research</i> 57:3026-31.
AM	Murray et al. (1998) "Matrix metalloproteinase-1 is associated with poor prognosis in eosophageal cancer." <i>J. Pathol.</i> 185:256-61.
AN	Murray et al. (1998) "Matrix metalloproteinases and their inhibitors in gastric cancer." <i>Gut</i> , 43:791-797.
AO	Savas et al. (1994) "Mouse Cytochrome P-450EF, Representative of a New 1B Subfamily of Cytochrome P-450's" <i>J. Biol. Chem.</i> 269:14905-11.
AP	Savas et al. (1997) "Biological Oxidation and P450 Reactions" <i>Arch. Biochem. Biophys.</i> , 347:181-92.
AQ	Schmidt & Bradfield (1996) "AH Receptor Signaling Pathways." <i>Annu. Rev. Cell Dev. Biol.</i> 12:55-89.
AR	Shen et al. (1994) "cDNA Cloning, Sequence Analysis, and Induction by Aryl Hydrocarbons of a Murine Cytochrome P450 Gene, Cyb1b1." <i>DNA Cell Biol.</i> 13:763-9.
AS	Shimada et al. (1996) "Activation of chemically diverse procarcinogens by human cytochrome P450 1B1" <i>Cancer Research</i> 56(13):2979-84.
AT	Sutter et al. (1994) "Complete cDNA Sequence of a Human Dioxin-inducible mRNA Identifies a New Gene Subfamily of Cytochrome P450 That Maps to Chromosome 2." <i>J. Biol. Chem.</i> 269:13092-9.
AU	Tailor, G. et al. (1998) "Detection of cytochrome P450 CYP1B1 in human tumors using monoclonal antibodies against a c-terminal decapeptide" <i>Human & Experimental Toxicology</i> . Vol. 17, no. 9, pp. 534. Proceedings of the British Toxicology Society Annual Congress Guilford, England, UK April 19-22, 1998. <i>British Toxicological Society</i> , abstract.
AV	Tang et al. (1996) "Isolation and Characterization of the Human Cytochrome P450 CYP1B1 Gene." <i>J. Biol. Chem.</i> , 271:28324-30.
AW	Tang et al. (1999) "Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1" <i>Drug Metabolism and Disposition</i> (1999 Feb) 27(2):274-80, abstract.
AX	Walker et al. (1995) "Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals." <i>Carcinogenesis</i> , 16:1319-27.
AY	Wang et al. (1998) "Functional and physical interactions between the estrogen receptor Sp1 and nuclear aryl hydrocarbon receptor complexes." <i>Nucl. Acid. Res.</i> 26:3044-52.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.